Immunotech Biopharm Ltd (6978.HK)
HKSE · HKD · Healthcare · Biotechnology
HK$0.345 (+0.00%) as of
Key statistics
- Market cap
- 213.04M
- EPS (TTM)
- -0.310
- Dividend yield
- 0.00%
- 52-week range
- 0.330 – 3.720
- Beta
- 0.09
- Profit margin
- 0.00%
- Volume
- 85.00k
About Immunotech Biopharm Ltd
Immunotech Biopharm Ltd, a cellular immunotherapy biopharmaceutical company, focuses on the research, development, and commercialization of T cell immunotherapy products for the treatment of cancers in the People's Republic of China. The company's core product is EAL, a multi-target cellular immunotherapy product that has completed Phase III clinical trials for the prevention of postsurgical recurrence of liver cancer. It also develops CAR-T-19 injection product for B-cell acute lymphoblastic leukaemia that is in Phase II/III clinical trial; 6B11-OCIK injection that is in Phase I clinical trial for ovarian cancer; RC19D2 for relapsed and refractory diffuse large B-cell lymphoma that is in Phase I clinical trial; and TCR-T cell series products to treat solid tumors. In addition, the company develops pre-clinical products, such as aT19 to treat hematologic malignancies; YT003 and YT008 for post transplantation infections; YT007 for solid tumors; and VAC-aT19 for hematologic malignancies. Immunotech Biopharm Ltd was founded in 2006 and is headquartered in Beijing, the People's Republic of China.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Beijing, China
- Employees
- 189
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.